The GP Health Department reported that the rollout of Lenacapavir, an HIV prevention drug, exceeded its targets in the first month of implementation. This development indicates a positive response to the drug's introduction in the region.

The rollout of lenacapavir (LEN) in Gauteng has faced challenges, with patients in parts of Pretoria being turned away due to delays. It has been two weeks since the initiation of the vaccination program, but access remains limited for some individuals, according to Health-e News.

Health-e News discusses the need for health system reform in South Africa to effectively combat tuberculosis (TB). The article emphasizes that while tools to end TB are available, the organization and financing of the health system must be improved to ensure these resources reach those in need.

A study on drug-resistant tuberculosis conducted in South Africa has shown transformative results in treatment approaches. The findings were published in the New England Journal of Medicine, highlighting significant advancements in managing this public health challenge.

Four South Africans from groups the government aims to reach with the six-monthly HIV prevention injection lenacapavir have shared their experiences, according to TimesLIVE. They explained why they chose the long-acting shot, described what happened during their clinic visits, and said whether they plan to return for another dose. The accounts offer insight into the rollout of the twice-yearly injection as part of South Africa's HIV prevention efforts.

According to The Citizen Business, South Africa loses approximately R26 billion annually due to water losses, with nearly half of its treated water not reaching end users.